FIFA World Cup Rule Change Proposal - Leading By 5 Goals Leads to an Automatic Win

By Fergus Nelson

With the FIFA World Cup 2026 approaching an assuredly dramatic and climactic finale, and with our home team England down to the last four, here at Presentient we have been reflecting about the competition so far. There has been much office water cooler discussion about the new 48 team format, the complicated rules for selecting the top 8 of 12 third placed finishers, and of course the goals, the cards and other controversies surrounding the competition.

But we’ve also been thinking about ways to improve the game and the parallels we can draw to our technology’s use in clinical trials. So, I propose a rule change: If either team is leading by 5 goals at any point in the match, they should automatically be declared the winner.

This may seem like a deliberately provocative statement, but I believe there are some merits to this idea, particularly when thinking about how this might apply to clinical trials.

It is worth noting that there are two ways you can view this new rule, each with their own perspectives, biases and consequences. Declaring the leading team the winner is an efficacy decision, whereas eliminating the trailing team is a futility decision. In football these decisions result from the same scoreline, however, in clinical trials, it is important to acknowledge they are different decisions, with different consequences if you get them wrong. 

The case for stopping early

Leading by 5 goals is significant. So significant in fact that in the entire 163 year history of the modern game a 5 goal lead has never been overturned in a top flight match. Even the greatest comebacks in football's history don't get there: Charlton Athletic's 7-6 win over Huddersfield Town in 1957 came from 5-1 down, and Barcelona's reversal of PSG in 2017 erased a 4-0 deficit, with the latter example played over two games. Whereas, a five goal lead is relatively quite common. In the 2024-2025 season alone 29 matches would have been stopped early across the top 5 European leagues (English Premier League, La Liga, Bundesliga, Serie A, and Ligue 1). Presentient’s BRAKES platform is able to detect when a trial has reached a level of statistical significance that is calibrated and configured to your particular trial, while remaining fully blinded.

Stopping early allows you to prepare early for the next game. The coaching staff can go home and start planning and preparing tactics for the next game. The stakes are a lot higher for clinical trials. Getting an early indication on the success of a phase two trial allows you to plan and prepare for the phase three trials, shortening the gap between trials and ultimately faster go to market

Stopping early allows you to rest your players. A dominant team that plays an exciting and aggressive game can gain an advantage by only playing a portion of the game leading to less fatigue and better recovery for their players. In clinical trials, being able to stop a trial early for success (or failure) allows you to more effectively allocate the finite resource of eligible participants and protect them from unnecessary risk.

The case against

In the interest of balance, we should also explore some of the legitimate criticism that the new rule proposal is likely to face.

Optimism bias. Every fan thinks that their team is special. That if only the players dig a little deeper, or the manager makes the perfect substitution they could pull it back. However, overturning a large deficit in sports is vanishingly rare. The historic failure rate for phase II trials is around 71% and phase III trials are not much better than a coin flip, with 42% ending in failure. Almost no one thinks it applies to them. In spite of these failure rates, every trial is funded by people with a good-faith belief that their treatment is effective and can bring genuine benefits to patients. This optimism however, leads to trials continuing longer than required.

Sunk cost and disappointed fans. The fans in the stadium have travelled from all around the world and paid thousands of dollars to watch their beloved team play for the full 90 minutes. Calling the result of the game early robs the fans of a full experience. However, the fact is, that when the result of the game is a foregone conclusion many fans will voluntarily leave early. In football there is little cost to continuing the game for the full 90 minutes, however, in clinical trials every month that the trial continues could cost millions to the sponsor, not to mention the opportunity cost of being slower to market and the patients that continue to receive a less effective treatment. 

Who makes the call?

In football everyone can see the scoreline and so the decision is easy. In a blinded clinical trial the scoreline is not available for humans to view. The BRAKES algorithm runs the interim analysis, analysing the trials scoreline, inside a secure enclave, outside the reach of human biases. The platform emits a signal for success or failure that clients can use to trigger their own interim analysis, timed at the optimum point in the trial. 

So, should FIFA adopt this?

Almost certainly not. Nobody wants a World Cup semi-final decided in the 60th minute. But this firmly tongue-in-cheek proposal is a fun way to discuss and recognise that continuing a match or clinical trial, long past the point where the outcome could be known, is a choice. That choice bears a cost, to the sponsor, to the patients still receiving a less effective treatment and to the next trial that could have started sooner.

The established methodology of clinical trials still makes that high stakes choice at huge cost to the industry. At Presentient we believe that there is a better choice available: one that increases trial efficiency, removes human bias from the decision and maintains blinding safeguards. That's what we built BRAKES to do.